2019年8月7日水曜日

PARTNER 3 TRIAL

Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
https://www.nejm.org/doi/full/10.1056/NEJMoa1814052

今回の論文は 超有名な パートナー3です。
TAVI対SAVRのガチンコ勝負で、1,高リスク、2,中リスクで勝利したTAVIが、今回の低リスクで3度交えます。今年春のACCで発表が終わった後に、スタンディングオベーションが起こったそうで、結果はTAVIの圧勝でした。
最近の弁膜症関連の学会では、内科外科に関わらず、必ず言及されていますし、一方で、この論文は素晴らしい。どんどん低リスクにもTAVIをすべき。という人もいれば、内科外科に関わらず、解釈には注意を要する。という人もいて、評価がマチマチなことも面白いところです。

背景
重症大動脈弁狭窄症に対するTAVIの役割はパートナー1,2試験などのエビデンスによって進化している。つまり手術リスクの高度、または中等度の患者においてはTAVIはSAVRより優れているまたは劣っていないと言う結果でありました。さらにテクノロジーの進化により、アメリカではTAVIはSAVRより多くなってきています。
しかし大部分のASの患者は低リスクですが、低リスク患者においてTAVIのエビデンスは十分にではない。このため低リスクの患者後の無作為試験を行うこととなった。

2ページ 
METHODS
この試験は多施設無作為試験である、TAVIは経大腿動脈アプローチで第3世代バルーン拡張型つまりサピエン3。この試験のスポンサーはもちろんエドワーズ社。

PATIENTS
インクルージョンクライテリアは高度石灰化大動脈弁狭窄症。外科的STSPROMスコア(項目はJACVSDとほぼ同じ)が4%以下の低リスクである。エクスクルージョンについて詳細はサプルメントに書いてあるとあります。解剖学的にTAVIが困難な症例は除外されています。

エンドポイント
1年後のあらゆる原因の死亡、脳梗塞、再入院。

3ページ 結果
71箇所、1000例がエントリー ほとんどがアメリカ。
TAVI503 AVR497
テーブル1
患者背景はTAVI、SAVRに違いがありません。

4ページ procedure outcome 
TAVIの7.9%、SAVRの26.4%が同時手技としてconcomitant procedureが行われています。
これまた詳細はサプルメントに書いてあるとあります。

4ページ右 Primary EP
これは6ページ Figure Aを見てください。これがこの論文のポイントです。
死亡、ストローク、再入院の個々では有意な差が出ませんが、左上、表Aでは、複合EPでTAVIの圧倒的勝利です。
低リスクの患者群で、SAVRの死亡率が1ヶ月で1.1%、再入院は6.5%。とちょっと高い気がします。
外科医が下手なんじゃないのと。外科側でよく言われていることです。

8ページ Table2 secondary EP
ここでもTAVIの圧倒的勝利です。

7ページ右下
Discussion
パートナー3試験の結果、低リスク群においても、TAVIはSAVRより優れているという結論です。
8ページ左下 段落
過去10年ではTAVI推奨は重度の症状のあるASでしたが、適応が拡大されていく。
現時点では、若い低リスクの患者にはTAVIは制限されている。
右段落
この試験でのSAVRの成績はよかった!!けれども、AR,脚ブロック、PM、冠動脈閉塞などの合併症の問題があるもののTAVIが勝ったとあります。
これらの合併症は大きな問題である気がしますが、サラッと書かれているだけですね。
9ページ 左上
この試験の最も重要なリミテーションは1年という短期であるということです。
SAVRの良好な長期成績と対抗するために、TAVIの場合はSVD、血栓弁の懸念があるので長期成績の検討が必要だとあります。これもさらっと書かれてます。
左下 次の段落
他にもリミテーションがあります。
大腿動脈アクセスが悪いものや、二尖弁、大きな石灰化があったりする、解剖学的に除外されている症例があるとさらっと書かれてます。


で、論文内で何度も、詳細はサプルメントに書いてあると出てくるのですが、そのサプルメントは74ページもあります。この論文自体は11ページなので、こっちのほうが本文じゃないの?って感じなのですが、実際に重要なことがたくさん書かれています。

サプルメント
38ページ concomitant procedure
TAVIは7.9%と数が少なく、ほとんどがPCI、PMです。一方、SAVRのほうは、26.4%と数が多い上に、かなりいろいろやってまして、、、患者背景は低リスクなんでしょうが、手術は結構踏み込んでいて、手術に関する予測死亡率はそこそこ高くなると思います。つまりこの試験のSAVR死亡率の高さは、手術が下手だからではなく、複雑な術式の妥当な結果ということがわかります。
じゃなんで外科医はこんな複雑な術式を選んだのか?といえばおそらく本能的なものだと思います。縮小手術で短期成績を追求するのを是としない。長期成績を改善してこその手術だということでしょう。
この状況で比較するというのは違和感があります。TAVIにPCIがあるのでSAVRにCABGがあるのは良いとしてもCABGのほうが倍多いです。


次 47-48ページ
懸念事項のPM、ブロックです。
PMは1年 TAVI7.3% SAVR5.4%、ブロックはTAVI23.7% SAVR8.0%と、それなりです。
わざわざページを換えてわかりにくくしているのは、少し悪意を感じます。

61ページ
一番上です。1520例から1000例になっています。ほとんど見えない字で、520例が除外されていることが書かれています。よく見ると解剖学的に除外されたのが308例あります。大腿動脈アクセスが悪いものや、二尖弁、大きな石灰化があったりするものだと思われますが、詳細はこれ以上書かれていません。

72ページ
ARですが、マイルドまで入れると30%ほどあります。石灰化の少ないように選ばれた症例にしては、ちょっと多い印象ですね。これが長期にどうかということですね。


私の解釈は、TAVIに適した解剖を持つ低リスクの患者群の短期成績は良い。という、わりと当たり前のもので、
SAVR群には、複雑な術式が紛れていることからも分かる通り、TAVIとの対決するSAVRに必ずしも適した患者群ではないということです。
MVRした患者を入れるならマイトラクリップをする患者も入れないと公平でないかもしれません。そうなると話があまりに混乱するので、そもそも複雑な術式になる場合は除外しておくのがいいのかもしれません。

また単独のエンドポイントで差がつかず、3つの複合エンドポイントを用いてようやく差がついた。ということなんだろうと思います。

リミテーションでも述べられていますが、低リスクの患者は長生きしますので、長期成績がポイントになると思います。
長期成績に影響するとされている、脚ブロックやPM、ARが、今後、どう影響するかは興味深いところです。
またSAVR群に複雑な術式が入ってきているのは、短期成績にはある程度目をつぶって長期成績を改善することを目指した結果とも言えるので、長期での結果は注目です。

ただ、最近の流れのとおり、長期成績が出る10年後には次の世代のデバイスが出現し、この議論が進まないというパターンかもしれません。

2019年1月24日木曜日

SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization in the FREEDOM Trial

SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization in the FREEDOM Trial

https://www.sciencedirect.com/science/article/pii/S073510971838690X?via%3Dihub


The FREEDOM trial
A multicenter trial that studied diabetic patients with multivessel native CAD without left main stenosis or chronic total occlusions that had an indication for myocardial revascularization and were candidates for either CABG or PCI. Patients were randomized to either CABG or PCI with drug-eluting stents.

They used HCE, not MACCE.
Hard cardiovascular events
Death from any cause, nonfatal MI, and nonfatal stroke.

SS is useful for PCI not CABG.

2019年1月9日水曜日

Impact of Complete Revascularization on Long-Term Outcomes After Coronary Artery Bypass Grafting in Patients With Left Ventricular Dysfunction

Impact of Complete Revascularization on Long-Term Outcomes After Coronary Artery Bypass Grafting in Patients With Left Ventricular Dysfunction
Circ J 2019; 83: 122–129

https://www.jstage.jst.go.jp/article/circj/83/1/83_CJ-18-0653/_pdf/-char/en

The long-term outcomes of complete revascularization (CR) in patients with left ventricular (LV) dysfunction undergoing coronary artery bypass grafting (CABG) remain unclear.

111 patients with LV ejection fraction ≤35% who underwent isolated first-time CABG:
 63 underwent CR
 48 underwent incomplete revascularization (IR).

At a median follow-up of 10.1 years, the rates of death from any cause, cardiac death, and MACCE were significantly greater in the IR group.

After adjusting for propensity score,
NO! significant difference was found between the CR and IR groups regarding death from any cause (hazard ratio [HR], 1.45; 95% CI: 0.75–2.81; P=0.271) and cardiac death (HR, 1.45; 95% CI: 0.68–3.10; P=0.337). In contrast, IR increased the risk of MACCE (HR, 1.92; 95% CI: 1.08–3.41; P=0.027), which was principally attributed to an increased risk of repeat revascularization (HR, 3.92; 95% CI: 1.34–11.44; P=0.013).

Although IR was not significantly associated with an increased risk of long-term mortality in patients with LV dysfunction who underwent CABG, CR might reduce the risks of repeat revascularization and subsequent MACCE.


Does the Cardiac Surgeon Accept Coronary Artery Bypass  Grafting With Incomplete Revascularization for Patients  With Low Ventricular Function and Complex  Multivessel Coronary Disease?

2018年12月31日月曜日

Prosthesis–Patient Mismatch in Patients Undergoing Transcatheter Aortic Valve Replacement

Prosthesis–Patient Mismatch in Patients Undergoing Transcatheter Aortic Valve Replacement


http://www.onlinejacc.org/content/72/22/2701


On the basis of the discharge echocardiographic effective valve area indexed to body surface area, PPM was classified as severe (<0 .65="" 0.85="" cm2="" m2="" moderate="" none="" or="" to="">0.85 cm2/m2). 

Severe and moderate PPM were present following TAVR in 12% and 25% of patients, respectively.

Severe PPM after TAVR was present in 12% of patients and was associated with higher mortality and HF rehospitalization at 1 year.



Generally, PPM after SAVR doesn't matter. Moreover, PPM might be thought as old fashion in new prosthetic aortic valve (Crown and Trifecta) era.
It seems that severe PPM after SAVR and TAVI is quite different.
It might be reason why the incidence of severe PPM after TAVI is generally less than SAVR.




2018年12月28日金曜日

Functional Mitral Regurgitation: Therapeutic Strategies for a Ventricular Disease

Functional Mitral Regurgitation: Therapeutic Strategies for a Ventricular Disease
J Cardiac Fail 2014;20:252 -267


ABSTRACT
Functional mitral regurgitation is a highly prevalent condition among patients with ischemic and dilated cardiomyopathies. Arising from remodeling of both the mitral valve annulus and the left ventricle, it is associated with high mortality and morbidity. In selected patients, cardiac resynchronization therapy helps to reduce functional mitral regurgitation, but surgical intervention remains the mainstay of therapy when medical therapy for left ventricular dysfunction has been inadequate. It is, however, associated with significant perioperative risks and does not alter long-term mortality. Percutaneous devices, and more recently the Mitraclip in particular, represent a promising alternative that can improve symptoms and ventricular remodeling with significantly lower periprocedural risk.



It remains unclear whether fMR repair is beneficial to this ventricular-valvular disease paradigm.
Current ACC/AHA and ESC guidelines do not make a distinction in recommended diagnostic modalities or in classification schema for severity, between fMR and
other etiologies of MR.
Medical therapy is limited in its ability to fully correct fMR.
CRT specifically targets myocardial dyssynchrony, which can be especially pronounced in those patients with segmental wall motion abnormalities and contributes to fMR.
MV surgery significantly reduces or eliminates fMR, reduces LV dimensions, and improves symptoms, but it is also associated with periprocedural complications,
such as mortality, bleeding, stroke, and renal dysfunction, and provides no clear long-term mortality benefit. There have been no randomized trials to compare the effectiveness of different surgical repair techniques.
Although there have been no prospective studies comparing the effects of MV surgery alone with the combination procedure of valve surgery and SVR, the combination procedure allowed for more consistent reduction in fMR but not
mortality, and they are accompanied by high perioperative risk.
Edge-to-Edge Repair (Mitraclip) corrects fMR with significantly lower periprocedural risk.

2018年12月27日木曜日

Pulmonary Hypertension

Pulmonary Hypertension

Two blood flow patterns of PH with different prognoses have been reported in patients with heart failure. In the most common, called post-capillary PH (IpcPH), PH is solely caused by increased left-sided filling pressures. However, 10-15% of patients have both pre- and post-capillary PH (CpcPH), characterized by high filling pressures and a pulmonary vascular component.

This form of PH has similarities with pulmonary arterial hypertension, and is defined by a combined elevation of mean pulmonary artery wedge pressure (mPAWP), a measure of pressure in the upper left heart chamber, or atrium; pulmonary vascular resistance (PVR), reflecting changes in arteries that supply blood to the lungs; and/or diastolic pressure gradient (DPG), which is the difference between pulmonary artery diastolic pressure and mean pulmonary capillary wedge pressure.


Old
Transpulmonary pressure gradient(TPG:mean PAP - mean PAWP)
12<  CpcPH,  12>  IpcPH

New
Diastolic pressure gradient (DPG : diastolic PAP - mean PAWP)
7<  CpcPH,  7>  IpcPH

PVR > 3.0 Wood CpcPH, PVR ≦ 3.0 Wood  IpcPH


Prognosis
CpcPH BAD
IpcPH better

2018年12月24日月曜日

Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk: Results From the PARTNER 2 Trial

https://www.ctsnet.org/jans/cost-effectiveness-transcatheter-versus-surgical-aortic-valve-replacement-patients-severe?utm_source=iContact&utm_medium=email&utm_campaign=ctsnet&utm_content=JANS+12%2F21%2F2018


Cost-effective analysis of TAVR versus SAVR in 3110 intermediate-risk aortic stenosis patients from the PARTNER-2 trial

Costs were ~$20,000 higher with TAVR than SAVR.
Total cost differences for the index hospitalization were
only $2888 higher with XT-TAVR (p=0.014) and
$4155 lower with S3-TAVR (p<0 .001="" nbsp="" p="">owing to reductions in length of stay with TAVR.

Follow-up costs were significantly lower with XT-TAVR (△-$9304; p<0 .001="" and="" compared="" nbsp="" p="" s3-tavr="" savr.="" with="">
Over a lifetime horizon, TAVR was projected to lower total costs by $8000-$10,000 and to increase quality-adjusted survival by 0.15-0.27 years.

 XT-TAVR and S3-TAVR were found to be economically dominant compared with SAVR in 84% and 97% of bootstrap replicates, respectively.


Q
TAVR Durability is same as SAVR? We'll see.
If the durability of TAVR is inferior, the results might be changed.

2018年12月21日金曜日

“Respect When You Can, Resect When You Should”: A Realistic Approach to Posterior Leaflet Mitral Valve Repair

“Respect When You Can, Resect When You Should”: A Realistic Approach to Posterior Leaflet Mitral Valve Repair

https://www.ctsnet.org/jans/%E2%80%9Crespect-when-you-can-resect-when-you-should%E2%80%9D-realistic-approach-posterior-leaflet-mitral-valve?utm_source=iContact&utm_medium=email&utm_campaign=ctsnet&utm_content=JANS+12%2F7%2F2018

J Thorac Cardiovasc Surg 2018;156:1856-66

“respect when you can, resect when you should” concept
 Resection was performed only if an excess tissue in height or width was present. The excess tissue in height was treated if P2, after a complete unfolding, was twice as high than P1 or P3. In such cases, a transverse resection of P2 was performed to bring it to approximately the same height as P1 and P3 (P2 being slightly higher than P1 and P3 in a normal valve).
This usually removes the rough area that was thickened. During this
operative step, great care was taken to individualize the secondary, and
even marginal, chordae that were at the adequate length (when compared
with the reference point) to resuspend the new free edge of P2. As far as
the excess in width is concerned, it was treated and carried out each time
there was an obvious and natural transverse folding of the leaflet. The
most objective way to evaluate such an excess of tissue in width was to
lay P2 on the posterior ventricular wall and to see if there was any natural
folding. When this happened, a small triangular resection was performed,
the base of the triangle being at the level of the free edge and the apex at the
annulus. A small resection was often effective in eliminating the excess
transverse tissue without putting the posterior leaflet (PL) under tension

2005 - 2015
701 consecutive  severe mitral regurgitation
441 degenerative:  376 posterior leaflet prolapse (24.7% isolated P2 and 75.3% P2 associated with other segments)

aged 65.8 ± 13 years, and 70.5% were male.
Median follow-up was 61.1 months.

There were 3 hospital deaths (0.8%). Reoperation was necessary in 7 patients (1.9%).

After 1, 5, and 10 years,
overall survival was 97.8%, 93.6%, and 86.7%
recurrent/residual >2+ mitral regurgitation was  0.7%, 1.9%, and 5.9%
New York Heart Association III/IV at 0.8%, 1.9%, and 5.3%.


2018年12月20日木曜日

Outcomes Following Surgical Revascularization With Single Versus Bilateral Internal Thoracic Arterial Grafts in Patients With Left Main Coronary Artery Disease Undergoing Coronary Artery Bypass Grafting: Insights From the EXCEL Trial

Outcomes Following Surgical Revascularization With Single Versus Bilateral Internal Thoracic Arterial Grafts in Patients With Left Main Coronary Artery Disease Undergoing Coronary Artery Bypass Grafting: Insights From the EXCEL Trial

Eur J Cardiothorac Surg. 2018 Aug 27. doi: 10.1093/ejcts/ezy291.

https://www.ctsnet.org/jans/outcomes-following-surgical-revascularization-single-versus-bilateral-internal-thoracic?utm_source=iContact&utm_medium=email&utm_campaign=ctsnet&utm_content=JANS+12%2F7%2F2018


The EXCEL trial randomized 1905 patients with left main coronary artery disease to percutaneous coronary intervention with everolimus-eluting stents versus CABG.
Among the 905 patients undergoing CABG, 688 (76.0%) received SITA and 217 (24.0%) received BITA.

The unadjusted 3-year composite primary endpoint of
death, stroke or myocardial infarction (MI)  15.6% of SITA = 11.6% of BITA
all-cause death 6.7% = 3.3%
Sternal wound dehiscence within 30 days 1.8% = 2.2%  !!!

CONCLUSIONS:
In the EXCEL trial, there were no clinical differences at 3 years between SITA or BITA revascularization in patients with left main coronary artery disease.

2018年12月9日日曜日

Outcomes Following Surgical Revascularization With Single Versus Bilateral Internal Thoracic Arterial Grafts in Patients With Left Main Coronary Artery Disease Undergoing Coronary Artery Bypass Grafting: Insights From the EXCEL Trial

https://www.ctsnet.org/jans/outcomes-following-surgical-revascularization-single-versus-bilateral-internal-thoracic?utm_source=iContact&utm_medium=email&utm_campaign=ctsnet&utm_content=JANS+12%2F7%2F2018



SITA vs. BITA

The EXCEL trial randomized 1905 patients with LMT coronary artery disease to percutaneous coronary intervention with everolimus-eluting stents versus CABG.

Among the 905 patients undergoing CABG, 688 (76.0%) received SITA and 217 (24.0%) received BITA.

The BITA group
younger (66.1 ± 9.5 vs 64.5 ± 9.3 years, P = 0.020)
less likely female (24.3% vs 14.3%, P = 0.002)
diabetic (28.8% vs 15.2%, P < 0.001)
a lower prevalence of peripheral vessel disease (10.2% vs 5.5%, P = 0.040).

The unadjusted 3-year composite primary endpoint of death, stroke or myocardial infarction (MI) occurred in 15.6% of SITA vs 11.6% of BITA patients (P = 0.17).

The SITA group tended to have a higher 3-year rate of all-cause death compared with the BITA group (6.7% vs 3.3%; P = 0.070).
Stroke, MI and ischaemia-driven revascularization outcomes were not significantly different between groups.

After adjusting for baseline differences, neither the composite of death, stroke or MI [hazard ratio (HR) 1.12, 95% confidence interval (CI) 0.71–1.78; P = 0.62] nor mortality (HR 1.36, 95% CI 0.60–3.12; P = 0.46) was significantly higher with SITA.
The rehospitalization rate after 3 years was higher in the SITA group (35.8% vs 26.0%, P = 0.008), a difference which was no longer present after multivariable adjustment (HR 1.27, 95% CI 0.93–1.74; P = 0.13).
Sternal wound dehiscence within 30 days did not occur more often in the BITA group compared to the SITA group (1.8% vs 2.2%, P > 0.99).

CONCLUSIONS
In the EXCEL trial, there were no clinical differences at 3 years between SITA or BITA revascularization in patients with left main coronary artery disease.


The selection of SITA or BITA was not randamized.
So probably SITA group had more likely complicated pts and worse results.
It seems to me that no differences and more comfortable with BITA due to less anastomosis.

2018年9月30日日曜日

Transcatheter Mitral-Valve Repair in Patients With Heart Failure

Transcatheter Mitral-Valve Repair in Patients With Heart Failure

https://www.ctsnet.org/jans/transcatheter-mitral-valve-repair-patients-heart-failure?utm_source=iContact&utm_medium=email&utm_campaign=ctsnet&utm_content=JANS+9%2F28%2F2018

This multicenter RCT study evaluated the efficacy of medical therapy plus transcatheter valve repair (MitraClip) to medical therapy alone for heart failure accompanied by secondary moderate to severe mitral regurgitation.

The device group experienced significantly fewer hospitalizations and lower mortality at 24 months follow-up.

Neither surgical repair nor surgical replacement of the mitral valve has been shown to lower the rate of hospitalization or death associated with secondary mitral regurgitation, and both procedures confer a substantial risk of complications.

Why are there the difference between surgery and MitraClip?

If surgery is too invasive, the mortality of surgical survivor must be improved.

According to MR improvement, MVR must be better than MVP and Mitraclip. But there were no differences between MVR and MVP.

I doubt some limitations affect the results.
1. Abbot's trial  It might cause COI.
2. F/U doctors know who are MitraClip patients due to XP.

2018年9月26日水曜日

Combined Transaortic and Transapical Approach to Septal Myectomy for Complex Long-Segment Hypertrophy

Combined Transaortic and Transapical Approach to Septal Myectomy for Complex Long-Segment Hypertrophy

https://www.ctsnet.org/article/combined-transaortic-and-transapical-approach-septal-myectomy-complex-long-segment?utm_source=iContact&utm_medium=email&utm_campaign=ctsnet&utm_content=Pulse+9%2F25%2F2018

Standard Morrow's myectomy + myectomy through LV apex 5cm incision

Aortic Valve Replacement With Right Anterior Thoracotomy, Sutureless Valves, and Ultrafast-Track Anesthesia: A Truly Minimally Invasive Approach in Ancona

Aortic Valve Replacement With Right Anterior Thoracotomy, Sutureless Valves, and Ultrafast-Track Anesthesia: A Truly Minimally Invasive Approach in Ancona

https://www.ctsnet.org/article/aortic-valve-replacement-right-anterior-thoracotomy-sutureless-valves-and-ultrafast-track?utm_source=iContact&utm_medium=email&utm_campaign=ctsnet&utm_content=Pulse+9%2F25%2F2018

MICS-AVR
Need the disrtance between Aortomy and aortic valve over 7cm
Standard antegrade CP x1
Sutureless valve Perceval (crimp)
Every Nadia 1 suture

2018年3月7日水曜日

Right Coronary Aneurysm With Coronary Arteriovenous Fistula to Right Atrium

https://www.ctsnet.org/article/right-coronary-aneurysm-coronary-arteriovenous-fistula-right-atrium

The fistula between the proximal of RCA and SVC

They had some choices
1 Open the fistula, and close the entry and exit through the fistula ( or through the SVC). No need bypass.
2 Close the proximal RCA and the exit through the fistula ( or through the SVC). need bypass.

They chose 2. Why? I am afraid that SVG long term patancy. maybe too close.

2018年1月31日水曜日

Minimally Invasive Aortic Valve Replacement by Thoracotomy: Step-by-Step Guide

https://www.youtube.com/watch?time_continue=3&v=nIRL52PpM-E

Preop
Assessment of incision level:  CT Coronal view, Aortic cross clamp above PA
4-0 prolene sutures on FA and FV.
FV cannulation: Valsalva manuever
FA cannulation: 15Fr (BSA<1 .6="" 17fr="" 19fr="">2.1)
Remove excess pericardial fat to visualize

Right Anterior Minithoracotomy AVR Intuity Valve for Bicuspid Aortic Stenosis

https://www.youtube.com/watch?time_continue=1&v=ckiAlZc0A_4

Intuity Valve  (Suture-less valve)
Very small incision 6cm?
Difficult even for valve sizers to enter thoracic space.
Use tourniquets for three valve sutures.

2018年1月15日月曜日

The use of preoperative aspirin in cardiac surgery: A systematic review and meta-analysis

http://onlinelibrary.wiley.com/doi/10.1111/jocs.13250/abstract

Aspirin is of benefit to patients following CABG.
Continuation or administration of preoperative aspirin before CABG or any cardiac surgical procedure remains controversial.

12 randomized controlled trials and 28 observational studies

Result
1
The use of preoperative aspirin in patients undergoing CABG at any dose is associated with reduced early mortality as well as a reduced incidence of postoperative acute kidney injury.
2
Low-dose aspirin (≤160 mg/d) is associated with a decreased incidence of perioperative myocardial infarction (MI).
3
Administration of preoperative aspirin at any dose in patients undergoing cardiac surgery increases postoperative bleeding. It did not increase the rates of surgical re-exploration due to excessive postoperative bleeding nor did it increase the rates of packed red blood cell transfusions (PRBC).

Bayaspirin 1T = 100mg

2018年1月12日金曜日

MitraClip : Minimally Invasive Mitral Valve Repair

https://www.youtube.com/watch?v=wgHiI-lSi1M&list=PLC9uVfWun4-QcEPD2CJKbW4imsaZ9LLYz&index=5&t=142s

エコーによる評価が非常に重要。
88F NYHA3 MR4
スタンダードは外科的僧帽弁形成術。
リスクが高い症例が良い適応。
中隔穿刺は僧帽弁に近づきすぎないことが大切。
術中左房圧を測定する。平均左房圧、V波が下がる。

2018年1月10日水曜日

Echo Assessment for MitraClip

https://www.youtube.com/watch?v=peVD1ch3S8E&list=PLC9uVfWun4-QcEPD2CJKbW4imsaZ9LLYz&index=7&t=35s


経食道エコー、3Dイメージングで、逆流量をかなり正確に測定できるようになった。
MitraClip後の僧帽弁狭窄の評価は心拍数を60前後にコントロールしてする。
僧帽弁狭窄になった場合はクリップをより真ん中に打ち直す。
心臓MRIでPISA使用で、かなり逆流量を測定できる。

2018年1月9日火曜日

Contemporary Trends in the Use and Outcomes of Surgical Treatment of Tricuspid Regurgitation

http://jaha.ahajournals.org/content/6/12/e007597

アメリカ、ウエストバージニア大

三尖弁の経皮的修復術の実現を見据えての現時点での状況を研究
アメリカ全体のデータベースを使用 三尖弁手術症例 N=45 477 !!!
2003-2014 12years!

(1)TRに対する手術はまれ。 ほとんどの三尖弁手術は他の心臓手術との合併組み合わせて行われる 。
(2)単独三尖弁手術患者は合併症例に比較してもともとリスクが高い。
(3)単独三尖弁手術後の院内死亡率は 過去10年間で大きく変化しなかった。
(4)単独三尖弁手術は、 術後合併症、長期入院、 コストが高い。単独三尖弁置換は永久ペースメーカ移植の割合が高い。

三尖弁手術。先天性やIE手術に比べてかなり増加している。
単独TVR N=795, 単独TVP N=569 (日本2014年 78/175なので年間数としては同じ。アメリカのほうが手術件数自体はかなり多いので全体に対する割合ではかなり低い)
死亡率が高い。10.9(TVR)/8.1%(TVP)!!!(日本2014年6.4/2.9%)
これは手術割合が低い(手術に消極的)からかもしれない。

手術症例が少なくて成績もそんなに良くないことから、経皮的修復術(MitraClip)の余地が十分という主張かな。

そもそも論として、日本やヨーロッパのように三尖弁手術を積極的にやってどうかが気になるところ。